## The Sustained Virologic Response in Chronic Hepatitis C Patients Treated with Interferon Mono-Therapy

Satoshi Shakado, Hiroshi Watanabe, Tetsuro Sohda, Kaoru Iwata, Makoto Irie, Yuji Kitamura, Yasuaki Takeyama, Yasuhiro Koyama, Hidetoshi Nakane, Daisuke Morihara, Takashi Tanaka, Masanori Yokoyama, Kazuhiro Maeda, Kunihiko Aoyagi and Shotaro Sakisaka

The Third Department of Medicine, Fukuoka University School of Medicine, Fukuoka, Japan

Abstract: Five hundred forty-four patients were underwent an interferon mono-therapy for chronic hepatitis C at Fukuoka University Hospital and an affiliated institutions from January 1992 to May 2005. A sustained virologic response (SVR) was obtained in 201 patients (37.0%). A statistical analysis demonstrated that SVR tended to be lower in elderly patients and it was significantly low in patients with a progressive fibrotic liver (p<0.05). Regarding the serotype and serum RNA levels of the virus in 379 patients, the SVR was as follows. In the serotype 1 group, the SVR was 11.1% and 62.5% in the high and low virus RNA group, respectively. In the serotype 2 group, the SVR was 40% and 68.6% in the high and low virus RNA group, respectively. In conclusion, interferon mono-therapy cannot provide a sufficient therapeutic effect in chronic hepatitis C patients with serotype 1 and a high HCV-RNA level. However, the present study revealed that interferon mono-therapy is recommended for young patients demonstrating an early liver fibrotic stage.

Key words: Chronic hepatitis C, Interferon, Sustained virologic response